Correlation Between Checkpoint Therapeutics and Brainstorm Cell

Can any of the company-specific risk be diversified away by investing in both Checkpoint Therapeutics and Brainstorm Cell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Checkpoint Therapeutics and Brainstorm Cell into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Checkpoint Therapeutics and Brainstorm Cell Therapeutics, you can compare the effects of market volatilities on Checkpoint Therapeutics and Brainstorm Cell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Checkpoint Therapeutics with a short position of Brainstorm Cell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Checkpoint Therapeutics and Brainstorm Cell.

Diversification Opportunities for Checkpoint Therapeutics and Brainstorm Cell

-0.26

Correlation Coefficient

Checkpoint Therapeutics  Brainstorm Cell

Very good diversification

The 3 months correlation between Checkpoint and Brainstorm is -0.26. Overlapping area represents the amount of risk that can be diversified away by holding Checkpoint Therapeutics and Brainstorm Cell Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Brainstorm Cell Ther and Checkpoint Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Checkpoint Therapeutics are associated (or correlated) with Brainstorm Cell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Brainstorm Cell Ther has no effect on the direction of Checkpoint Therapeutics i.e., Checkpoint Therapeutics and Brainstorm Cell go up and down completely randomly.

Pair Corralation between Checkpoint Therapeutics and Brainstorm Cell

Given the investment horizon of 90 days Checkpoint Therapeutics is expected to under-perform the Brainstorm Cell. But the stock apears to be less risky and, when comparing its historical volatility, Checkpoint Therapeutics is 1.33 times less risky than Brainstorm Cell. The stock trades about -0.11 of its potential returns per unit of risk. The Brainstorm Cell Therapeutics is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  171.00  in Brainstorm Cell Therapeutics on December 2, 2024 and sell it today you would lose (11.00) from holding Brainstorm Cell Therapeutics or give up 6.43% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Checkpoint Therapeutics  vs.  Brainstorm Cell Therapeutics

Checkpoint Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Checkpoint Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Brainstorm Cell Ther

Risk-Adjusted Performance

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Brainstorm Cell Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite fairly strong essential indicators, Brainstorm Cell is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders.

Pair Trading with Checkpoint Therapeutics and Brainstorm Cell

The main advantage of trading using opposite Checkpoint Therapeutics and Brainstorm Cell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Checkpoint Therapeutics position performs unexpectedly, Brainstorm Cell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Brainstorm Cell will offset losses from the drop in Brainstorm Cell's long position.

The idea behind Checkpoint Therapeutics and Brainstorm Cell Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.